Pliant Therapeutics (PLRX) Competitors $1.34 -0.05 (-3.24%) As of 12:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PLRX vs. CMPS, AARD, ABEO, GLUE, LFCR, RNAC, IVA, NGNE, FHTX, and ZYBTShould you be buying Pliant Therapeutics stock or one of its competitors? The main competitors of Pliant Therapeutics include COMPASS Pathways (CMPS), Aardvark Therapeutics (AARD), Abeona Therapeutics (ABEO), Monte Rosa Therapeutics (GLUE), Lifecore Biomedical (LFCR), Cartesian Therapeutics (RNAC), Inventiva (IVA), Neurogene (NGNE), Foghorn Therapeutics (FHTX), and Zhengye Biotechnology (ZYBT). These companies are all part of the "pharmaceutical products" industry. Pliant Therapeutics vs. Its Competitors COMPASS Pathways Aardvark Therapeutics Abeona Therapeutics Monte Rosa Therapeutics Lifecore Biomedical Cartesian Therapeutics Inventiva Neurogene Foghorn Therapeutics Zhengye Biotechnology Pliant Therapeutics (NASDAQ:PLRX) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability. Do analysts prefer PLRX or CMPS? Pliant Therapeutics currently has a consensus price target of $13.31, suggesting a potential upside of 889.78%. COMPASS Pathways has a consensus price target of $17.00, suggesting a potential upside of 347.96%. Given Pliant Therapeutics' higher possible upside, analysts plainly believe Pliant Therapeutics is more favorable than COMPASS Pathways.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pliant Therapeutics 0 Sell rating(s) 12 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00COMPASS Pathways 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Do institutionals & insiders hold more shares of PLRX or CMPS? 97.3% of Pliant Therapeutics shares are held by institutional investors. Comparatively, 46.2% of COMPASS Pathways shares are held by institutional investors. 6.4% of Pliant Therapeutics shares are held by insiders. Comparatively, 3.9% of COMPASS Pathways shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media refer more to PLRX or CMPS? In the previous week, COMPASS Pathways had 6 more articles in the media than Pliant Therapeutics. MarketBeat recorded 8 mentions for COMPASS Pathways and 2 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 1.81 beat COMPASS Pathways' score of 0.54 indicating that Pliant Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pliant Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive COMPASS Pathways 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, PLRX or CMPS? COMPASS Pathways has lower revenue, but higher earnings than Pliant Therapeutics. COMPASS Pathways is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPliant Therapeutics$1.58M52.26-$210.30M-$3.61-0.37COMPASS PathwaysN/AN/A-$155.12M-$1.99-1.91 Which has more risk and volatility, PLRX or CMPS? Pliant Therapeutics has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.12, meaning that its stock price is 112% more volatile than the S&P 500. Is PLRX or CMPS more profitable? Pliant Therapeutics' return on equity of -67.56% beat COMPASS Pathways' return on equity.Company Net Margins Return on Equity Return on Assets Pliant TherapeuticsN/A -67.56% -52.54% COMPASS Pathways N/A -81.75%-59.42% SummaryPliant Therapeutics beats COMPASS Pathways on 8 of the 14 factors compared between the two stocks. Get Pliant Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLRX vs. The Competition Export to ExcelMetricPliant TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$82.57M$2.92B$5.56B$9.26BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-0.3720.2728.5819.56Price / Sales52.26298.79434.47183.65Price / CashN/A43.1536.0257.93Price / Book0.277.668.165.58Net Income-$210.30M-$55.11M$3.24B$257.82M7 Day Performance-1.10%0.03%-0.64%-0.39%1 Month Performance-1.10%7.47%4.93%7.80%1 Year Performance-90.04%-3.28%26.04%12.95% Pliant Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLRXPliant Therapeutics4.4603 of 5 stars$1.35-3.2%$13.31+889.8%-89.5%$82.57M$1.58M-0.3790Positive NewsCMPSCOMPASS Pathways1.7918 of 5 stars$3.31+1.5%$17.00+413.6%-50.0%$305.01MN/A0.00120Analyst ForecastAnalyst RevisionAARDAardvark TherapeuticsN/A$13.92flat$33.00+137.1%N/A$302.01MN/A0.0018ABEOAbeona Therapeutics3.7246 of 5 stars$5.75-2.4%$19.25+234.8%+10.4%$301.31M$3.50M-4.5390Analyst ForecastGLUEMonte Rosa Therapeutics2.1704 of 5 stars$4.97+2.1%$15.33+208.5%+24.8%$299.55M$75.62M60.8890LFCRLifecore Biomedical1.3327 of 5 stars$8.22+2.2%$8.00-2.7%+53.5%$297.68M$128.26M-5.67690Positive NewsRNACCartesian Therapeutics2.2211 of 5 stars$10.77-3.9%$40.67+277.6%-24.2%$290.95M$38.91M0.0064IVAInventiva3.163 of 5 stars$3.02+0.3%$10.40+244.4%+21.4%$287.94M$9.95M0.00100Gap UpNGNENeurogene3.2151 of 5 stars$19.50-2.9%$46.17+136.8%-53.3%$286.52M$930K0.0090FHTXFoghorn Therapeutics2.0836 of 5 stars$4.78-6.8%$12.13+153.7%-7.2%$285.95M$22.60M0.00120ZYBTZhengye BiotechnologyN/A$5.54-8.4%N/AN/A$285.36M$25.53M0.00278Positive News Related Companies and Tools Related Companies CMPS Alternatives AARD Alternatives ABEO Alternatives GLUE Alternatives LFCR Alternatives RNAC Alternatives IVA Alternatives NGNE Alternatives FHTX Alternatives ZYBT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLRX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredAll New Social Security Numbers coming July 23?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pliant Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pliant Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PLRX Stock Alerts